Literature DB >> 18948376

Population-specific GSTM1 copy number variation.

R Stephanie Huang1, Peixian Chen, Steve Wisel, Shiwei Duan, Wei Zhang, Edwin H Cook, Soma Das, Nancy J Cox, M Eileen Dolan.   

Abstract

As one of the major glutathione conjugation enzymes, GSTM1 detoxifies a number of drugs and xenobiotics. Its expression and activity have been shown to correlate both with cancer risks and drug resistance. Through a genome-wide association study, we identified a significant association between HapMap SNP rs366631 and GSTM1 expression. In this study, utilizing lymphoblastoid cell lines derived from International HapMap Consortium CEU and YRI populations, we designed and performed site-specific genotyping assays for both rs366631 and a highly homologous GSTM1 upstream site. Copy number variation (CNV) assays were performed for three different regions of the GSTM1 gene. We demonstrated that HapMap SNP rs366631 is a non-polymorphic site. The false genotyping call arises from sequence homology, a common GSTM1 region deletion and a non-specific genotyping platform used to identify the SNP. However, the HapMap call for rs366631 genotype is an indicator of GSTM1 upstream region deletion. Furthermore, this upstream deletion can be used as a marker of GSTM1 gene deletion. Using a novel GSTM1 CNV assay, we showed a population-specific CNV in this region upstream of the gene. More than 75% of the Caucasian (CEU) samples exhibit GSTM1 deletion and none contain two copies of GSTM1. In contrast, up to 25% of African (YRI) samples were found to have two copies of GSTM1. In conclusion, HapMap rs366631 is a pseudo-SNP that can be used as a GSTM1 deletion marker. Both the pseudo-SNP allele frequency and GSTM1 upstream region CNV show population-specific patterns between CEU and YRI samples.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18948376      PMCID: PMC2722188          DOI: 10.1093/hmg/ddn345

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  30 in total

1.  Fine-scale structural variation of the human genome.

Authors:  Eray Tuzun; Andrew J Sharp; Jeffrey A Bailey; Rajinder Kaul; V Anne Morrison; Lisa M Pertz; Eric Haugen; Hillary Hayden; Donna Albertson; Daniel Pinkel; Maynard V Olson; Evan E Eichler
Journal:  Nat Genet       Date:  2005-05-15       Impact factor: 38.330

2.  Common deletion polymorphisms in the human genome.

Authors:  Steven A McCarroll; Tracy N Hadnott; George H Perry; Pardis C Sabeti; Michael C Zody; Jeffrey C Barrett; Stephanie Dallaire; Stacey B Gabriel; Charles Lee; Mark J Daly; David M Altshuler
Journal:  Nat Genet       Date:  2006-01       Impact factor: 38.330

3.  Detection and relevance of germline genetic polymorphisms in glutathione S-transferases (GSTs) in breast cancer patients from northern Indian population.

Authors:  Anubha Saxena; Varinderpal S Dhillon; Mohammad Raish; Mohammad Asim; Shabeena Rehman; N K Shukla; S V S Deo; Anjum Ara; Syed Akhtar Husain
Journal:  Breast Cancer Res Treat       Date:  2008-06-24       Impact factor: 4.872

Review 4.  Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis.

Authors:  Zheng Ye; Honglin Song
Journal:  Eur J Cancer       Date:  2005-05       Impact factor: 9.162

5.  Global gene expression as a function of germline genetic variation.

Authors:  Deborah French; Mark R Wilkinson; Wenjian Yang; Luc de Chaisemartin; Edwin H Cook; Soma Das; Mark J Ratain; William E Evans; James R Downing; Ching-Hon Pui; Mary V Relling
Journal:  Hum Mol Genet       Date:  2005-04-27       Impact factor: 6.150

6.  The role of glutathione-S-transferase polymorphisms in ovarian cancer survival.

Authors:  Christina M Nagle; Georgia Chenevix-Trench; Amanda B Spurdle; Penelope M Webb
Journal:  Eur J Cancer       Date:  2006-11-03       Impact factor: 9.162

7.  Effect of population and gender on chemotherapeutic agent-induced cytotoxicity.

Authors:  Rong Stephanie Huang; Emily O Kistner; Wasim K Bleibel; Sunita J Shukla; M Eileen Dolan
Journal:  Mol Cancer Ther       Date:  2007-01       Impact factor: 6.261

8.  Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients.

Authors:  Katja Ott; Florian Lordick; Karen Becker; Kurt Ulm; JörgRüdiger Siewert; Heinz Höfler; Gisela Keller
Journal:  Int J Colorectal Dis       Date:  2008-04-29       Impact factor: 2.571

9.  Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans.

Authors:  Rong Stephanie Huang; Shiwei Duan; Emily O Kistner; Wei Zhang; Wasim K Bleibel; Nancy J Cox; M Eileen Dolan
Journal:  Pharmacogenet Genomics       Date:  2008-06       Impact factor: 2.089

Review 10.  Glutathione S-transferase polymorphisms: cancer incidence and therapy.

Authors:  C C McIlwain; D M Townsend; K D Tew
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

View more
  15 in total

1.  Identification of copy number variation hotspots in human populations.

Authors:  Wenqing Fu; Feng Zhang; Yi Wang; Xun Gu; Li Jin
Journal:  Am J Hum Genet       Date:  2010-10-08       Impact factor: 11.025

2.  Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.

Authors:  Stuart A Scott; Manishkumar Patel; Suparna Martis; Steven A Lubitz; Sarina van der Zee; Chang Yoo; Lisa Edelmann; Jonathan L Halperin; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2011-12-21       Impact factor: 2.533

3.  Gene expression analysis of whole blood, peripheral blood mononuclear cells, and lymphoblastoid cell lines from the Framingham Heart Study.

Authors:  Roby Joehanes; Andrew D Johnson; Jennifer J Barb; Nalini Raghavachari; Poching Liu; Kimberly A Woodhouse; Christopher J O'Donnell; Peter J Munson; Daniel Levy
Journal:  Physiol Genomics       Date:  2011-11-01       Impact factor: 3.107

4.  Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology.

Authors:  P David Josephy
Journal:  Hum Genomics Proteomics       Date:  2010-06-13

5.  Association between copy number variation losses and alcohol dependence across African American and European American ethnic groups.

Authors:  Alvaro E Ulloa; Jiayu Chen; Victor M Vergara; Vince Calhoun; Jingyu Liu
Journal:  Alcohol Clin Exp Res       Date:  2014-02-11       Impact factor: 3.455

6.  An X chromosome-wide association study in autism families identifies TBL1X as a novel autism spectrum disorder candidate gene in males.

Authors:  Ren-Hua Chung; Deqiong Ma; Kai Wang; Dale J Hedges; James M Jaworski; John R Gilbert; Michael L Cuccaro; Harry H Wright; Ruth K Abramson; Ioanna Konidari; Patrice L Whitehead; Gerard D Schellenberg; Hakon Hakonarson; Jonathan L Haines; Margaret A Pericak-Vance; Eden R Martin
Journal:  Mol Autism       Date:  2011-11-04       Impact factor: 7.509

7.  Genome-wide CNV analysis replicates the association between GSTM1 deletion and bladder cancer: a support for using continuous measurement from SNP-array data.

Authors:  Gaëlle Marenne; Francisco X Real; Nathaniel Rothman; Benjamin Rodríguez-Santiago; Luis Pérez-Jurado; Manolis Kogevinas; Montse García-Closas; Debra T Silverman; Stephen J Chanock; Emmanuelle Génin; Núria Malats
Journal:  BMC Genomics       Date:  2012-07-20       Impact factor: 3.969

8.  Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation.

Authors:  S Martis; H Mei; R Vijzelaar; L Edelmann; R J Desnick; S A Scott
Journal:  Pharmacogenomics J       Date:  2012-11-20       Impact factor: 3.550

9.  Worldwide population distribution of the common LCE3C-LCE3B deletion associated with psoriasis and other autoimmune disorders.

Authors:  Laia Bassaganyas; Eva Riveira-Muñoz; Manel García-Aragonés; Juan R González; Mario Cáceres; Lluís Armengol; Xavier Estivill
Journal:  BMC Genomics       Date:  2013-04-17       Impact factor: 3.969

10.  GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?

Authors:  Robert P Young; Raewyn J Hopkins; Bryan A Hay; Gregory D Gamble
Journal:  Appl Clin Genet       Date:  2011-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.